Kate Vandyke

Research Interests

Cancer Cell Biology Cancer Therapy Haematological Tumours Cancer Biology and Clinical Oncology

Dr Kate Vandyke

Senior Research Fellow

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

I am lead of the Myeloma Research Laboratory, Faculty of Health and Medical Sciences, University of Adelaide, based at the South Australian Health and Medical Research Institute (SAHMRI), Precision Medicine Theme.My research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.https://aurora.adelaide.edu.au/userprofile.html?uid=3778&em=true#

https://health.adelaide.edu.au/florey120anniversary/our-current-health-leaders/decoding-myeloma-cancer

Current projects include:
  • Defining major cellular and molecular mechanisms that drive tumour dissemination in multiple myeloma
  • Identifying how changes to the myeloma bone marrow microenvironment drive disease progression for MGUS and smouldering myeloma to multiple myeloma
  • Identification of novel serum biomarkers that enable the identification of high-risk MGUS, smouldering myeloma and multiple myeloma patients
  • Using novel drug delivery strategies to increase tumour drug uptake and decrease off-target side-effects in multiple myeloma and paediatric brain cancers
  • Identification of novel therapeutic targets for the treatment of high-risk multiple myeloma

PhD projects available

Using cutting-edge multiomic approaches to clinically relevant tumour vulnerabilities in multiple myeloma

To improve outcomes for multiple myeloma patients, we urgently need to identify novel pathways that contribute to myeloma development, drug resistance and relapse. Our data suggest that the growth of myeloma tumour cells is critically dependent on the expression of genes from several specific metabolic pathways, suggesting that adaptive changes in myeloma cell metabolism plays a critical role in tumour growth. In this project, CRISPR gRNA screens and metabolomics will be used to dissect the metabolic dependencies of myeloma tumours, using both patient-derived samples and cutting-edge mouse models. By pinpointing the critical metabolic pathways that fuel tumour growth, we aim to identify new, precise therapeutic targets that could revolutionise myeloma treatment.

Projects available for: PhD, Honours

Location: SAHMRI

Research project start: Semester 1 and 2

 

Date Position Institution name
2021 - ongoing Co-lead, Myeloma Research Laboratory University of Adelaide
2020 - ongoing Senior research fellow South Australian Health and Medical Research Institute
2018 - 2021 Beat Cancer Early Career Research Fellow University of Adelaide, Adelaide
2017 - 2018 Post-doctoral Research Scientist University of Adelaide, Adelaide
2013 - 2016 Mary Overton Early Career Research Fellow SA Pathology
2012 - 2018 Affiliate Lecturer University of Adelaide
2012 - 2013 Multiple Myeloma Research Foundation Research Fellow SA Pathology
2010 - 2012 Post-doctoral Research Scientist SA Pathology
2007 - 2010 Technical assistant (part time) SA Pathology
2005 - 2006 Research Assistant Prince of Wales Hospital

Date Institution name Country Title
2007 - 2010 University of Adelaide Australia PhD
2000 - 2004 University of New South Wales Australia BMedSci (Hons)

Year Citation
2025 Kumorkiewicz-Jamro, A., Pachulicz, R. J., Fitter, S., Górska, R., Duggan, J., Vandyke, K., . . . Zannettino, A. C. W. (2025). Atriplex hortensis var. 'rubra' extracts and purified amaranthin-type pigments reduce oxidative stress and inflammatory response in LPS-stimulated RAW264.7 cells. Food Chemistry, 462, 14 pages.
DOI Scopus9 WoS9 Europe PMC2
2025 Duggan, J., Yu, L., Fitter, S., Kumorkiewicz-Jamro, A., Vandyke, K., Bulone, V., & Zannettino, A. (2025). Apple Pomace Polyphenols Extracted by Deep Eutectic Solvent Ameliorate Lipopolysaccharide-Induced Inflammation in RAW264.7 Murine Macrophages and Human Monocyte-Derived Macrophages. ACS Food Science and Technology, 5(4), 1354-1364.
DOI Scopus2 WoS2
2025 Plakhova, N., Panagopoulos, V., Cantley, M. D., Trainor, L. J., Hewett, D. R., Clark, K. C., . . . Vandyke, K. (2025). Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.. Leukemia, 39(6), 1464-1475.
DOI Scopus1 WoS3 Europe PMC1
2025 Clark, J. R., Panagopoulos, V., Noll, J. E., Mrozik, K. M., Bradey, A. L., Croucher, P. I., . . . Hewett, D. R. (2025). Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanism. Experimental Hematology, 150(ARTN 104842), 1-15.
DOI
2025 McCaughan, G., Beer, H., Bryant, C., Ho, P. J., King, T., Lee, C., . . . Quach, H. (2025). Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Internal Medicine Journal, 55(10), 1741-1751.
DOI
2025 Yong, A., Vandyke, K., Augustson, B., McCaughan, G., Talaulikar, D., Szabo, F., . . . Lee, C. H. S. (2025). Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia. EXPERT REVIEW OF HEMATOLOGY, 10 pages.
DOI
2025 Swan, D., Yong, A., Vandyke, K., & Hocking, J. (2025). Myeloma bone disease: A constant problem in the changing landscape of myeloma management. British Journal of Haematology, 14 pages.
DOI
2024 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Wallington-Gates, C. T., Spencer, A., . . . Zannettino, A. C. W. (2024). Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leukemia Research, 139, 107469-1-107469-8.
DOI Scopus7 WoS6 Europe PMC6
2024 Lill, C. B., Fitter, S., Zannettino, A. C. W., Vandyke, K., & Noll, J. E. (2024). Molecular and cellular mechanisms of chemoresistance in paediatric pre–B cell acute lymphoblastic leukaemia. Cancer and Metastasis Reviews, 43(4), 1385-1399.
DOI Scopus4 WoS3 Europe PMC3
2023 Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624.
DOI Scopus5 WoS5 Europe PMC4
2023 Plakhova, N., Panagopoulos, V., Vandyke, K., Zannettino, A. C. W., & Mrozik, K. M. (2023). Mesenchymal stromal cell senescence in haematological malignancies. Cancer and Metastasis Reviews, 42(1), 277-296.
DOI Scopus28 WoS25 Europe PMC21
2022 Ebert, L. M., Vandyke, K., Johan, M. Z., DeNichilo, M., Tan, L. Y., Myo Min, K. K., . . . Bonder, C. S. (2022). Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 16(6), 1221-1240.
DOI Scopus11 WoS12 Europe PMC11
2021 Opperman, K. S., Vandyke, K., Psaltis, P. J., Noll, J. E., & Zannettino, A. C. W. (2021). Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer and Metastasis Reviews, 40(1), 273-284.
DOI Scopus22 WoS21 Europe PMC21
2021 Vandyke, K. (2021). Seed and soil revisited in multiple myeloma.. Blood, 137(17), 2282-2283.
DOI Scopus1 Europe PMC1
2020 Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS One, 15(1), e0228408-1-e0228408-25.
DOI Scopus3 WoS14 Europe PMC3
2020 Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., . . . Vandyke, K. (2020). Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer letters, 475, 99-108.
DOI Scopus27 WoS26 Europe PMC25
2020 Mrozik, K. M., Cheong, C. M., Hewett, D. R., Noll, J. E., Opperman, K. S., Adwal, A., . . . Zannettino, A. C. W. (2020). LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.. FASEB Bioadv, 2(6), 339-353.
DOI Scopus5 WoS6 Europe PMC9
2020 Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20.
DOI Scopus10 WoS10 Europe PMC9
2020 Friend, N. L., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., . . . Zannettino, A. C. W. (2020). Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB BioAdvances, 2(9), 554-572.
DOI Scopus7 WoS6 Europe PMC8
2020 Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187.
DOI Scopus22 WoS22 Europe PMC19
2020 Zeissig, M. N., Zannettino, A. C. W., & Vandyke, K. (2020). Tumour dissemination in multiple myeloma disease progression and relapse: A potential therapeutic target in high-risk myeloma. Cancers, 12(12), 3643-1-3643-20.
DOI Scopus8 WoS7 Europe PMC8
2019 Khoo, W. H., Ledergor, G., Weiner, A., Roden, D. L., Terry, R. L., McDonald, M. M., . . . Croucher, P. I. (2019). A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 134(1), 30-43.
DOI Scopus116 WoS107 Europe PMC106
2019 Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787.
DOI Scopus65 WoS62 Europe PMC54
2018 Mrozik, K., Blaschuk, O., Cheong, C., Zannettino, A., & Vandyke, K. (2018). N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer, 18(1), 1-16.
DOI Scopus294 WoS282 Europe PMC238
2017 Hemming, S., Cakouros, D., Codrington, J., Vandyke, K., Arthur, A., Zannettino, A., & Gronthos, S. (2017). EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture & structural integrity and accelerates remodeling. FASEB Journal, 31(3), 1011-1027.
DOI Scopus54 WoS56 Europe PMC53
2017 Vuckovic, S., Vandyke, K., Rickards, D., McCauley Winter, P., Brown, S., Mitchell, T., . . . Hutchinson, A. (2017). The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. British Journal of Haematology, 177(3), 423-440.
DOI Scopus32 WoS31 Europe PMC30
2017 Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616.
DOI Scopus42 WoS40 Europe PMC36
2017 Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463.
DOI Scopus50 WoS47 Europe PMC44
2017 Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981.
DOI Scopus18 WoS17 Europe PMC16
2016 Hemming, S., Cakouros, D., Vandyke, K., Davis, M. J., Zannettino, A. C. W., & Gronthos, S. (2016). Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. Stem Cells and Development, 25(12), 909-921.
DOI Scopus69 WoS67 Europe PMC58
2016 Ng, J., Hynes, K., White, G., Sivanathan, K., Vandyke, K., Bartold, P., & Gronthos, S. (2016). Immunomodulatory properties of induced pluripotent stem cell-derived mesenchymal cells. Journal of Cellular Biochemistry, 117(12), 2844-2853.
DOI Scopus41 WoS41 Europe PMC36
2015 Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
DOI Scopus36 WoS36 Europe PMC35
2015 Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399.
DOI Scopus31 WoS29 Europe PMC28
2015 Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16.
DOI Scopus35 WoS35 Europe PMC33
2015 Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354.
DOI Scopus35 WoS33 Europe PMC29
2014 Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585.
DOI Scopus41 WoS39 Europe PMC42
2014 Ahmed, F., Dutta, N., Zannettino, A., Vandyke, K., & Choudhury, N. (2014). Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules, 15(4), 1276-1287.
DOI Scopus22 WoS18 Europe PMC10
2013 Vandyke, K., Chow, A., Williams, S., To, L., & Zannettino, A. (2013). Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology, 161(4), 499-507.
DOI Scopus17 WoS19 Europe PMC18
2013 Arthur, A., Panagopoulos, R., Cooper, L., Menicanin, D., Parkinson, I., Codrington, J., . . . Gronthos, S. (2013). EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 28(4), 926-935.
DOI Scopus42 WoS35 Europe PMC39
2013 Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76.
DOI Scopus26 WoS26 Europe PMC23
2012 Fitter, S., Vandyke, K., Gronthos, S., & Zannettino, A. (2012). Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 48(3), 229-240.
DOI Scopus57 WoS52 Europe PMC54
2011 Vandyke, K., Fitter, S., & Zannettino, A. (2011). The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal, 1(2), E2.
DOI Scopus22 WoS21 Europe PMC13
2010 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Schultz, C., Sims, N., & Zannettino, A. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759-1770.
DOI Scopus87 WoS81 Europe PMC75
2010 Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767.
DOI Scopus52 WoS50 Europe PMC45
2010 Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774.
DOI Scopus129 WoS114 Europe PMC99
2009 Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159.
DOI Scopus37 WoS35 Europe PMC36
2009 Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997.
DOI Scopus49 WoS48 Europe PMC43
2007 Vandyke, K., White, M. Y., Nguyen-Khuong, T., Ow, K., Luk, S. C. W., Kingsley, E. A., . . . Russell, P. J. (2007). Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo. Neoplasia, 9(4), 322-331.
DOI Scopus8 WoS8 Europe PMC7
2007 Vandyke, K., Jackson, P., Rowe, A., Russell, P. J., & Blair, J. M. (2007). Androgen decreases osteoprotegerin expression in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 10(2), 160-166.
DOI Scopus2 WoS3 Europe PMC2
1995 ANTONINI, J. M., VANDYKE, K., DIMATTEO, M., & REASOR, M. J. (1995). ATTENUATION OF ACUTE INFLAMMATORY EFFECTS OF SILICA IN RAT LUNG BY 21-AMINOSTEROID, U74389G. INFLAMMATION, 19(1), 9-21.
DOI WoS15

Year Citation
2025 Vandyke, K., Plakhova, N., Panagopoulos, V., Cantley, M., Trainor, L., Clark, K., . . . Mrozik, K. (2025). Mesenchymal Stromal Cell Senescence is Associated with Progression from MGUS to Multiple Myeloma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 25 (pp. 2 pages). CIG MEDIA GROUP, LP.
2023 Williams, C., Noll, J., Harnas, D., Parkinson, H., Hewett, D., Wyllie, K., . . . Panagopoulos, V. (2023). Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma. In BLOOD Vol. 142 (pp. 3 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS3
2023 Cheney, E. A. J., Harnas, D., Noll, J., Vandyke, K., Zannettino, A., & Hewett, D. (2023). Towards an IMiD sensitive C57BL/KaLwRij murine model of multiple myeloma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 23 (pp. S135). CIG MEDIA GROUP, LP.
2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS1
2013 Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION.
2008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel™) Inhibits Oteoclast Activity <i>in Vitro</i> and <i>in Vivo</i> Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY.
1992 WOODFORK, K. A., WONDERLIN, W. F., VANDYKE, K., & STROBL, J. S. (1992). THE EFFECT OF K+ CHANNEL BLOCKERS ON PROLIFERATION AND CA++-ACTIVATED K+ CURRENTS IN MCF-7 BREAST-CANCER CELLS. In MOLECULAR BIOLOGY OF THE CELL Vol. 3 (pp. A175). AMER SOC CELL BIOLOGY.
1986 VANDYKE, C., VANDYKE, K., CATERSON, B., SZUSTKIEWICZ, C., & REICH, A. (1986). ENHANCED-DURATION-CHEMILUMINESCENCE-IMMUNOASSAY (EDLIA) USING HORSE RADISH PEROXIDASE-LUMINOL-HYDROGEN PEROXIDE-PARA IODOPHENOL (PIP) - CONFIRMATION AND EXTENSION OF THE SYSTEM. In FEDERATION PROCEEDINGS Vol. 45 (pp. 732). FEDERATION AMER SOC EXP BIOL.
1985 THORNTON, M., VANDYKE, K., VANDYKE, C., & DIBARTOLOMEO, A. (1985). SENSITIVITY DIFFERENCES OF PLATELET ACTIVATING FACTOR (PAF) AND LYSO PAF ON CHEMI-LUMINESCENCE (CL) BETWEEN GRANULOCYTES OF NORMAL AND ARTHRITIC PATIENTS. In FEDERATION PROCEEDINGS Vol. 44 (pp. 1839). FEDERATION AMER SOC EXP BIOL.
WoS1
1984 PEDEN, D., VANDYKE, K., & EDINBORO, L. (1984). THE DISCONJUGATE INHIBITION OF N-FORMYL-METHIONYL-LEUCINYL-PHENYLALANINE INDUCED NEUTROPHIL CHEMI-LUMINESCENCE AND AGGREGATION BY NORDIHYDROGUIARETIC ACID AND INDOMETHACIN. In FEDERATION PROCEEDINGS Vol. 43 (pp. 953). FEDERATION AMER SOC EXP BIOL.
1984 EDINBORO, L., VANDYKE, K., & CASTRANOVA, V. (1984). EFFECTS OF PLATELET ACTIVATING FACTOR ON MEMBRANE-POTENTIAL AND RESPIRATORY BURST ACTIVITY OF HUMAN-GRANULOCYTES. In FEDERATION PROCEEDINGS Vol. 43 (pp. 461). FEDERATION AMER SOC EXP BIOL.
WoS2
1983 VANDYKE, K., CASTRANOVA, V., & VANDYKE, C. J. (1983). ANTI-INFLAMMATORY DRUG EFFECTS ON LUMINOL-DEPENDENT CHEMI-LUMINESCENCE (CL) FROM HUMAN-GRANULOCYTES STIMULATED BY CA++ IONOPHORE (A23187) AND BY THE REDUCED OR OXIDIZED FORMS OF A FORMYL PEPTIDE (FMLP OR FMOXLP). In FEDERATION PROCEEDINGS Vol. 42 (pp. 698). FEDERATION AMER SOC EXP BIOL.
WoS1
1982 VANDYKE, K., ENGLISH, D., PEKOE, G., PEDEN, D., MENGOLI, H., & CASTRANOVA, V. (1982). MULTIPURPOSE RADIOMATIC AUTOMATED FLOW LIQUID SCINTILLATION-COUNTER SYSTEM FOR MEASUREMENT OF BURST OR DELAYED CHEMI-LUMINESCENCE REACTIONS - MODEL-DRUG INHIBITION WITH LUMINOL DEPENDENT MYELOPEROXIDASE REACTION. In FEDERATION PROCEEDINGS Vol. 41 (pp. 1549). FEDERATION AMER SOC EXP BIOL.
1982 PEKOE, G. M., PEDEN, D., & VANDYKE, K. (1982). ANTIOXIDANT EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AGAINST PMN MYELOPEROXIDASE INFLAMMATORY FREE-RADICALS MEASURED BY LUMINOL-ENHANCED CHEMI-LUMINESCENCE (CL). In FEDERATION PROCEEDINGS Vol. 41 (pp. 1549). FEDERATION AMER SOC EXP BIOL.
1981 VANDYKE, K. (1981). DETERMINATION OF WATER HARDNESS RESIDUES ON CLOTHS AFTER TERG-O-TOMETER TESTING. In JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY Vol. 58 (pp. A591). AMER OIL CHEMISTS SOC.
1981 CASTRANOVA, V., JONES, G. S., PHILLIPS, R. M., PEDEN, D., & VANDYKE, K. (1981). ABNORMALITIES ASSOCIATED WITH CHRONIC GRANULOMATOUS-DISEASE. In FEDERATION PROCEEDINGS Vol. 40 (pp. 753). FEDERATION AMER SOC EXP BIOL.
WoS1
1980 JONES, G. S., WILSON, M. E., VANDYKE, K., & CASTRANOVA, V. (1980). DETERMINATION OF TRANSMEMBRANE POTENTIAL IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES. In FEDERATION PROCEEDINGS Vol. 39 (pp. 2100). FEDERATION AMER SOC EXP BIOL.
1979 UDEINYA, I. J., & VANDYKE, K. (1979). INHIBITION OF PARASITIZATION AND MEMBRANE GLYCOPROTEIN SYNTHESIS IN PLASMODIUM-FALCIPARUM BY TUNICAMYCIN AND 2-DEOXYGLUCOSE. In FEDERATION PROCEEDINGS Vol. 38 (pp. 543). FEDERATION AMER SOC EXP BIOL.
WoS1
1979 VANDYKE, K., UDEINYA, J., VANDYKE, C., BRISTER, C., & WILSON, M. (1979). LUMINOL-DEPENDENT CHEMI-LUMINESCENCE ANALYSIS (LDCA) OF HUMAN NEUTROPHILS - EFFECT OF ANTI-INFLAMMATORY DRUGS AND ENVIRONMENTAL-POLLUTANTS. In FEDERATION PROCEEDINGS Vol. 38 (pp. 441). FEDERATION AMER SOC EXP BIOL.
1978 WILSON, M. E., TRUSH, M. A., SCHREIBER, R. D., & VANDYKE, K. (1978). LUMINOL-DEPENDENT CHEMILUMINESCENCE ANALYSIS (LDCA) OF ALTERNATIVE PATHWAY DEFECTS IN PREMATURE HUMAN NEONATES. In FEDERATION PROCEEDINGS Vol. 37 (pp. 710). FEDERATION AMER SOC EXP BIOL.
1978 UDEINYA, I. J., & VANDYKE, K. (1978). BLOCKADE BY PURINE-6 SULFONIC-ACID 3N OXIDE OF UPTAKE, PHOSPHORYLATION AND POLYMERIZATION OF HYPOXANTHINE-H-3 BY MALARIA PARASITES. In FEDERATION PROCEEDINGS Vol. 37 (pp. 605). FEDERATION AMER SOC EXP BIOL.
1977 TRUSH, M., VANDYKE, K., ROBINSON, R., URQUILLA, P., SMITH, D., TAYLOR, M., . . . CRAIG, C. R. (1977). EVIDENCE THAT MOST OF CATECHOLAMINES IN CHROMAFFIN GRANULES ARE STORED WITHOUT ASSOCIATED ATP. In FEDERATION PROCEEDINGS Vol. 36 (pp. 383). FEDERATION AMER SOC EXP BIOL.
1977 URQUILLA, P. R., VANDYKE, K., & TRUSH, M. (1977). CONTRACTILE EFFECTS OF PYRIMIDINE NUCLEOTIDES IN CANINE CEREBRAL-ARTERIES. In FEDERATION PROCEEDINGS Vol. 36 (pp. 1035). FEDERATION AMER SOC EXP BIOL.
WoS6
1977 WILSON, M., TRUSH, M., & VANDYKE, K. (1977). EFFECT OF IONOPHORE A23187 ON CHEMILUMINESCENCE BY HUMAN GRANULOCYTES. In FEDERATION PROCEEDINGS Vol. 36 (pp. 1071). FEDERATION AMER SOC EXP BIOL.
WoS5
1976 VANDYKE, K., CARTER, G., TRUSH, M., & MAWHINNEY, M. G. (1976). INHIBITORY EFFECT OF 2 DEOXYGLUCOSE AND 5-THIO-D-GLUCOSE ON PHOSPHORYLATION OF ADENOSINE-H-3 AND INCORPORATION INTO NUCLEIC-ACIDS OF MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 35 (pp. 749). FEDERATION AMER SOC EXP BIOL.
1976 TRUSH, M. A., VANDYKE, K., & RAMANAN, S. (1976). INHIBITION OF PHAGOCYTOSIS-LINKED LIGHT-EMISSION FROM HUMAN GRANULOCYTES BY PROMETHAZINE - EXAMPLE OF PHOTOPHARMACOLOGY. In FEDERATION PROCEEDINGS Vol. 35 (pp. 748). FEDERATION AMER SOC EXP BIOL.
WoS1
1976 URQUILLA, P. R., VANDYKE, K., & ROBINSON, R. (1976). RELAXANT EFFECTS OF ADENINE NUCLEOSIDES AND NUCLEOTIDES ON CANINE CEREBRAL-ARTERIES. In FEDERATION PROCEEDINGS Vol. 35 (pp. 699). FEDERATION AMER SOC EXP BIOL.
WoS3
1975 VANDYKE, K., & NEWCOMER, C. (1975). EFFECT OF PURINE ANTIMETABOLITES ON PHOSPHORYLATION OF HYPOXANTHINE-H-3 IN ERYTHROCYTE-FREE MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 34 (pp. 807). FEDERATION AMER SOC EXP BIOL.
WoS1
1975 ROWE, J. N., VANDYKE, K., WESTFALL, D. P., & STITZEL, R. E. (1975). INVITRO SYNTHESIS OF ATP IN GUINEA-PIG VAS-DEFERENS. In FEDERATION PROCEEDINGS Vol. 34 (pp. 739). FEDERATION AMER SOC EXP BIOL.
WoS2
1974 MANANDHA, M. S., & VANDYKE, K. (1974). PURINE-SALVAGE METABOLISM IN FREE MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 33 (pp. 592). FEDERATION AMER SOC EXP BIOL.
WoS4
1974 VANDYKE, K., & MANANDHA, M. S. (1974). ULTRASENSITIVE DELAYED LUMINESCENCE ANALYSIS (DLA) FOR ALL NATURALLY OCCURRING NUCLEOTIDE TRIPHOSPHATES. In FEDERATION PROCEEDINGS Vol. 33 (pp. 480). FEDERATION AMER SOC EXP BIOL.
1974 MANANDHA, M. S., VANDYKE, K., & ROBINSON, R. L. (1974). METABOLISM OF GUANOSINE-H-3 IN PERFUSED HEART. In FEDERATION PROCEEDINGS Vol. 33 (pp. 385). FEDERATION AMER SOC EXP BIOL.
1973 VANDYKE, K., & CARTER, G. W. (1973). POSSIBLE NEW ROLE FOR ADRENAL-MEDULLA - READY SUPPLY OF PURINES FOR HEART AND LUNGS. In FEDERATION PROCEEDINGS Vol. 32 (pp. 740-&). FEDERATION AMER SOC EXP BIOL.
WoS2
1972 STEVENS, P., STITZEL, R. E., VANDYKE, K., & ROBINSON, R. L. (1972). SPECIES DIFFERENCE IN DEMONSTRATION OF NUCLEOTIDE LABELING OF CATECHOLAMINE-ATP COMPLEX IN CHROMAFFIN GRANULES OF ADRENAL-MEDULLA. In FEDERATION PROCEEDINGS Vol. 31 (pp. A521-&). FEDERATION AMER SOC EXP BIOL.
1971 VANDYKE, K., STEVENS, P., & ROBINSON, R. L. (1971). DEMONSTRATION OF DYNAMIC NATURE OF ATP IN CATECHOLAMINE-ATP COMPLEX OF ADRENAL GLAND. In FEDERATION PROCEEDINGS Vol. 30 (pp. A445-&). FEDERATION AMER SOC EXP BIOL.
1970 LANTZ, C., & VANDYKE, K. (1970). SELECTIVE EFFECT OF INTERCALATING DRUGS ON ACTIVITY OF RNA POLYMERASE OF MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 29 (pp. A808-+). FEDERATION AMER SOC EXP BIOL.
WoS1
1969 VANDYKE, K., MCCARTHY, J., FURNER, R., & STITZEL, R. (1969). PATHOLOGICAL EFFECTS OF MALARIA INFECTION ON HOST MICROSOMAL DRUG-METABOLIZING ENZYMES. In FEDERATION PROCEEDINGS Vol. 28 (pp. 366-&). FEDERATION AMER SOC EXP BIOL.
WoS1
1969 BERGHEI, P., VANDYKE, K., MCCLELLA, T., SZUSTKIE, C., & LANTZ, C. (1969). INHIBITORY EFFECTS OF ANTIMETABOLITES AND INTERCALATING ANTIBIOTICS ON INCORPORATION OF ADENOSINE-8-3HINTO NUCLEIC ACIDS OF MALARIAL PARASITE. In FEDERATION PROCEEDINGS Vol. 28 (pp. 361-&). FEDERATION AMER SOC EXP BIOL.
1968 VANDYKE, K., STITZEL, R., MCCLELLA, T., & SZUSTKIE, C. (1968). A SENSITIVE AND SPECIFIC DETERMINATION OF ATP BY AN AUTOMATED METHOD. In FEDERATION PROCEEDINGS Vol. 27 (pp. 841-&). FEDERATION AMER SOC EXP BIOL.
1968 VANDYKE, K., TREMBLAY, G. C., SZUSTKIE, C., & SAXE, L. H. (1968). PRELIMINARY STUDIES OF PURINE AND PYRIMIDINE INCORPORATION AND BIOSYNTHESIS INTO NUCLEIC ACIDS OF RAT BLOOD PARASITIZED BY PLASMODIUM BERGHEI. In JOURNAL OF PROTOZOOLOGY Vol. S 15 (pp. 23-&). SOC PROTOZOOLOGISTS.
WoS20
1967 DAVIS, S., & VANDYKE, K. (1967). EFFECT OF PROSCILLARIDIN IN COMBATTING SIMULATED CONGESTIVE HEART FAILURE AND DISAPPEARANCE OF TRITIATED DRUG FROM SEVERAL TISSUES. In FEDERATION PROCEEDINGS Vol. 26 (pp. 782-&). FEDERATION AMER SOC EXP BIOL.
1967 VANDYKE, K., & SZUSTKIE, C. (1967). A SENSITIVE AND SPECIFIC DETERMINATION OF SOME L-ALPHA AMINO ACIDS BY AN AUTOMATED METHOD. In FEDERATION PROCEEDINGS Vol. 26 (pp. 469-&). FEDERATION AMER SOC EXP BIOL.
1966 VANDYKE, K., & KATZMAN, P. A. (1966). EFFECT OF PMS ON ACTIVITY OF RNA POLYMERASE AND SYNTHESIS OF NUCLEIC ACIDS IN OVARIES OF IMMATURE RATS. In FEDERATION PROCEEDINGS Vol. 25 (pp. 286-&). FEDERATION AMER SOC EXP BIOL.
WoS1

Year Citation
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated Desmoglein-2 Surface Expression Is an Independent Predictor of Poor Outcome in Multiple Myeloma. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated desmoglein-2 surface expression is a predictor of poor outcome in multiple myeloma. Poster session presented at the meeting of Poster, SA Cancer Clinical Research Symposium.
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated desmoglein-2 surface expression is an independent predictor of poor outcome in multiple myeloma. Poster session presented at the meeting of Oral, Australian Society for Medical Research (ASMR) National Scientific Conference.
2023 Parkinson, H., Breen, J., Hin, N., Panagopoulos, V., Zannettino, A., Vandyke, K., & Hewett, D. (2023). A Functional Genomic Screen to Identify Novel Genes Involved in Multiple Myeloma Tumour Development. Poster session presented at the meeting of Abstracts of the 65th Annual Meeting of the American Society of Hematology (ASH), as published in Blood. CA, San Diego: American Society of Hematology.
DOI
2023 Trainor, L. J., Cantley, M. D., King, C., Plakhova, N., Skinner, M., Chai, R., . . . Zannettino, A. (2023). Profiling of patient bone marrow adipocytes in the myeloma microenvironment. Poster session presented at the meeting of Abstracts of the 20th Annual Meeting and Exposition of the International Myeloma Society (IMS 2023), as published in Clinical Lymphoma Myeloma and Leukemia. Athens, Greece: Elsevier.
DOI
2019 Opperman, K., Vandyke, K., Psaltis, P., Croucher, P., Noll, J., & Zannettino, A. (2019). Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
DOI
2019 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI
2008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
DOI
Date Role Grant Funding Body Amount
Grants
2024-2027 CIA Cancer Australia Priority-driven Collaborative Cancer Research Scheme Project Grant Cancer Australia AUD$595,467
2024-2028 CIA NHMRC Ideas Grant NHMRC AUD$1,494,105
2023-2026 CoI SSMF Starting Grant Svenska Sällskapet för Medicinsk Forskning AUD$869,836
2021-2023 CIA Cancer Australia Priority-driven Young Investigator Grant Cancer Australia/Cure Cancer Australia/Snowdome Foundation AUD$198,813
2019-2022 CoI Strategic Ecosystem Research Partnerships Leukaemia Foundation AUD$596,198
2019 - 2021 CIA Cancer Australia Priority-driven Young Investigator Grant Cancer Australia/Cure Cancer Australia/Leukaemia Foundation AUD$198,596
2017-2018 CIA Cancer Australia Priority-driven Young Investigator Grant Cure Cancer Australia AUD$199,454
2016 CIA Project Grant Royal Adelaide Hospital Contributing Haematologists' Committee AUD$25,000
2016 CIE Project Grant Royal Adelaide Hospital Research Fund AUD$50,000
Date Title Funding Body Amount
Fellowships
2018-2021 Beat Cancer Early Career Cancer Research Fellowship Cancer Council SA AUD$240,000
2013-2015 Mary Overton Early Career Fellowship Royal Adelaide Hospital AUD$252,000
2013-2015 Veronika Sacco Early Career Fellowship Florey Medical Research Foundation AUD$222,003
2011 MMRF Research Fellow Award Multiple Myeloma Research Foundation (USA) AUD$74,146

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor Development and optimisation of tumour vasculature modifying agents to improve drug delivery and enhance treatment outcomes in myeloma Doctor of Philosophy Doctorate Full Time Miss Teena Elise Siapkas
2025 Co-Supervisor Development and optimisation of tumour vasculature modifying agents to improve drug delivery and enhance treatment outcomes in myeloma Doctor of Philosophy Doctorate Full Time Miss Teena Elise Siapkas
2024 Principal Supervisor Modulating the blood-brain barrier to optimise drug delivery and treatment outcomes in diffuse midline gliomas (DMG) Doctor of Philosophy Doctorate Full Time Miss Tace Sian Conlin
2024 Co-Supervisor Genetic and biochemical characterisation of the SIK3 mutation, R393H: A causal mutation that helps define a new family of human monogenetic disorders Doctor of Philosophy Doctorate Full Time Eliana Gloria Stanziano
2024 Principal Supervisor Modulating the blood-brain barrier to optimise drug delivery and treatment outcomes in diffuse midline gliomas (DMG) Doctor of Philosophy Doctorate Full Time Miss Tace Sian Conlin
2024 Co-Supervisor Genetic and biochemical characterisation of the SIK3 mutation, R393H: A causal mutation that helps define a new family of human monogenetic disorders Doctor of Philosophy Doctorate Full Time Eliana Gloria Stanziano
2022 Co-Supervisor Lipidomic and metabolomic profiling of the bone marrow microenvironment to understand multiple myeloma disease development Doctor of Philosophy Doctorate Part Time Miss Mackenzie Rose Skinner
2022 Co-Supervisor Lipidomic and metabolomic profiling of the bone marrow microenvironment to understand multiple myeloma disease development Doctor of Philosophy Doctorate Full Time Miss Mackenzie Rose Skinner
2020 Principal Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Part Time Miss Laura Joy Trainor
2020 Principal Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Full Time Miss Laura Joy Trainor

Date Role Research Topic Program Degree Type Student Load Student Name
2020 - 2025 Co-Supervisor Identification of novel genes involved in multiple myeloma tumorigenesis Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson
2020 - 2025 Principal Supervisor Development of Vasculature-Modifying Strategies to Enhance Bortezomib Efficacy and Reduce Side Effects in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ms Sadia Munir
2019 - 2023 Co-Supervisor The Role of Bone Marrow Mesenchymal Stromal Cell Senescence in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova
2019 - 2021 Co-Supervisor Macrophages, Myeloma, Mouse Models and Methodologies Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman
2017 - 2020 Principal Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Zeissig
2013 - 2017 Co-Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong
2012 - 2018 Co-Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik

Date Role Committee Institution Country
2024 - ongoing Member South Australian Cancer Research Biobank (SACRB) Strategy & Governance Committee South Australian Cancer Research Biobank Australia
2023 - ongoing Member Myeloma Australia Myeloma Scientific Advisory Group (MSAG) Research Pillars Committee Myeloma Australia Australia
2015 - ongoing Member Women's and Children's Hospital Foundation Research Grants Committee - -
2014 - ongoing Member Australian Society for Medical Research SA Committee - -

Date Role Membership Country
2021 - ongoing Member International Myeloma Society United States
2019 - ongoing Member Australasian Leukaemia and Lymphoma Group Australia
2015 - ongoing - Haematology Society of Australia and New Zealand -
2014 - ongoing Member Australian Society for Medical Research -

Date Role Editorial Board Name Institution Country
2022 - ongoing Associate Editor Frontiers in Oncology Editorial Board Frontiers Switzerland
2020 - ongoing Associate Editor Journal of Bone Oncology Editorial Board Elsevier Germany
2020 - ongoing Associate Editor BMC Cancer Editorial Board BMC United Kingdom

Connect With Me

External Profiles

Other Links